老王加速器橘子版

Annals of the Rheumatic Diseases (ARD) is an official journal of EULAR and the home for innovative rheumatology research.

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research, including the most important recommendations for the management of various conditions.

ARD is an official journal of v2ray安卓版下载.

Free lay summaries are provided for selected research articles and all EULAR recommendations. You can keep up with the latest news via Twitter and Facebook.

Listen to the ARD podcast and subscribe in all podcast platforms, including Apple Podcast, Google Podcasts, Stitcher and v2ray手机端怎么设置

Editor-in-Chief: Professor Josef Smolen, Medical University of Vienna, Austria
Editorial team

COVID-19: a message from BMJ >>

老王加速器橘子版

Annals of the Rheumatic Diseases considers unsolicited submissions of a variety of article types, including original research articles (extended and concise reports), viewpoints, and letters to the Editor.

The Author Information section provides general guidelines and requirements for specific article types.

Information is also provided on editorial policies and open access.

Author information

Submit a paper

老王加速器橘子版

CORRESPONDENCE RESPONSE:

Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma

CORRESPONDENCE:

COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine

v2ray安卓版下载

Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh

v2rayng苹果客户端下载

Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma

v2ray安卓客户端下载

More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia

老王加速器橘子版

Rheumatoid arthritis
v2ray安卓客户端下载
Systemic lupus erythematosus
Psoriatic arthritis
Spondyloarthritis
Epidemiology
Systemic sclerosis
Autoinflammatory disorders
Paediatric rheumatology
Inflammatory arthritis

v2ray安卓客户端下载

老王加速器橘子版

Epidemiology:

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Osteoarthritis:

Does cartilage loss cause pain in osteoarthritis and if so, how much?

v2ray手机端怎么设置

The microbiome in rheumatology: Where are we and where should we go?

Systemic lupus erythematosus:

Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort

Spondyloarthritis:

High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics

老王加速器橘子版

The EULAR Standing Committees regularly establish and publish recommendations for the treatment of various rheumatic disorders. Each of these recommendations is developed by a group of specialists in their field. All EULAR recommendations are free to access.

The June 2023 and January 2023 issues of ARD contains all of the latest recommendations, including:

Management of rheumatoid arthritis with synthetic and biological DMARDs

Management of psoriatic arthritis with pharmacological therapies

Management of lupus nephritis

Management of Sjögren’s syndrome with topical and systemic therapies

Management of large vessel vasculitis

v2rayng免费节点每天更新

Vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Generic core competences of health professionals in rheumatology

The role of the nurse in the management of chronic inflammatory arthritis

Use of big data in rheumatic and musculoskeletal diseases

老王加速器橘子版

Correspondence:

有人知道v2ray怎么绕过学校的封锁吗 - 网络技术(Networking ...:2021-2-25 · 签名档 15秋西灵小向导 16天仙瀑营地小装逼 16小五台营地小装逼小押后16春龙门涧总装逼 16夏大五台小装逼 16夏凤坨梁向导 16夏阳台山向导 16夏东灵-百花总装逼 16夏阿尼玛卿小装逼 16秋百花总装逼 17天仙瀑A2训练 17小五台营地小装逼！非小压

Psoriatic arthritis:

DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study

Correspondence response:

Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma

Correspondence:

COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine

Correspondence response:

Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al

Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma

COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine

Response to: ‘COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine’ by Teh

Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma

More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia

v2ray安卓客户端 下载

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Does cartilage loss cause pain in osteoarthritis and if so, how much?

The microbiome in rheumatology: Where are we and where should we go?

Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort

High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics

DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study

Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma

COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine

Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al

v2ray安卓客户端下载